The U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) to … [+] Regeneron Pharmaceuticals for the experimental antibody cocktail REGN-COV2 for treatment of Covid-19. (Photo by Lev Radin/Pacific Press/LightRocket via Getty Images)
Pacific Press/LightRocket via Getty Images
Hip, hip, EUA.
That could be Regeneron Pharmaceuticals’ reaction to the news on Saturday about their product REGEN-CoV2, the antibody cocktail that U.S. President Donald Trump received when he had Covid-19. This combination of casirivimab and imdevimab has now received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to treat mild to moderate Covid-19 in people who are 12 years and older and at least 40 kg in weight. Forty kilograms is about four-fifths the weight of an octopus in case you are wondering.
Casirivimab and imdevimab may seem like great words for Scrabble when you stuck with a bunch of “v’s” and “i’s” and want something besides the Coldplay song “Viva la Vida.” But they are also recombinant human IgG1 monoclonal antibodies. The word “recombinant” comes from “recombine,” as in recombining genetic material in different ways in the laboratory to produce new types of antibodies. Antibodies are proteins that can bind and potentially neutralize specific proteins such as those that are part of an invading virus.
In this case, the proteins that casirivimab and imdevimab target are the spikes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus looks like a very, very small spiky massage ball.…